Global Health Investment Corporation

THE CORPORATION IS ORGANIZED AND SHALL BE OPERATED EXCLUSIVELY FOR SOCIAL (CONTINUED SCHEDULE O) (CONTINUED FROM FORM 990, PAGE 1 PART I) WELFARE PURPOSES WITHIN THE MEANING OF SECTION 501(C)(4) OF THE INTERNAL REVENUE CODE OF 1986, AS IT BE AMENDED, INCLUDING THE RELIEF OF THE POOR AND DISTRESSED OR OF THE UNDERPRIVILEGED; THE PROMOTION OF SOCIAL WELFARE AND THE LESSENING OF THE BURDENS OF GOVERNMENT. IN FURTHERANCE OF THESE PURPOSES, THE CORPORATION MAY SEEK WAYS TO PROVIDE AFFORDABLE FINANCING TO SUPPORT THE DEVELOPMENT OF DRUGS, VACCINES, PREVENTATIVES, DIAGNOSTICS AND OTHER PRODUCTS OR SERVICES TO ADDRESS GLOBAL HEALTH CHALLENGES THAT DISPROPORTIONATELY IMPACT DEVELOPING COUNTRIES. IN SO DOING, THE CORPORATION MAY SERVE AS MANAGING MEMBER OR GENERAL PARTNER OF ONE OR MORE INVESTMENT FUNDS ESTABLISHED PRIMARILY TO FURTHER SUCH PURPOSES.

ACHIEVING FINANCIAL CLOSE OF THE GLOBAL HEALTH INVESTMENT FUND I ON 19 DECEMBER 2013, WITH CAPITAL COMMITMENTS OF $108,365,000. THE ORGANIZATION SERVES AS GENERAL PARTNER/MANAGING MEMBER OF THE GLOBAL HEALTH INVESTMENT FUND, AND ALSO PROVIDED A CAPITAL COMMITMENT TO THE FUND ALONGSIDE THE OTHER LIMITED PARTNERS. THE FUND'S CAPITAL WAS INVESTED INTO TWELVE PORTFOLIO INVESTMENTS DURING YEARS 2012-2018. THE ORGANIZATION MANAGED THE FUND'S PORTFOLIO COMPANY INVESTMENTS, RESULTING IN REVENUE TO THE FUND AND DISTRIBUTIONS TO THE ORGANIZATION AND THE OTHER LIMITED PARTNERS OF THE FUND. INVESTMENT BY THE ORGANIZATION AS LIMITED PARTNER IN ADJUVANT CAPITAL GLOBAL HEALTH INVESTMENT FUND DE, IN THE AMOUNT OF $22 MILLION, IN 2019. (CONTINUED SCHEDULE O) (CONTINUED FROM PART III, 4A) COMMITTED INVESTMENT OF $3,333,332 IN BIOLINQ INCORPORATED DURING 2021. IN ADDITION, DURING 2021, THE CORPORATION ENTERED INTO A $16,598,000 AGREEMENT WITH U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE'S BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY ("BARDA") TO CARRY OUT ACTIVITIES THAT FOSTER AND ACCELERATE THE DEVELOPMENT AND INNOVATION OF MEDICAL COUNTERMEASURES. THE AGREEMENT, UNLIKE TYPICAL FEE FOR SERVICE OR COST REIMBURSEMENT PROCUREMENT GRANTS, WAS STRUCTURED AS AN OTHER TRANSACTION AGREEMENT ("OTA") OF WHICH BARDA, WITH THE AUTHORITY UNDER APPLICABLE LAW, MAY ENTER INTO TRANSACTIONS OTHER THAN PROCUREMENT CONTRACTS, GRANTS, COOPERATIVE AGREEMENTS, AND ARE NOT SUBJECT TO FEDERAL ACQUISITION REGULATION.SUBSEQUENT TO DECEMBER 31, 2021, THE CORPORATION ENTERED INTO VARIED MATERIAL CONTRACTS WITH UNRELATED PARTIES AS EITHER ADDITIONAL INCOME FUNDING MECHANISMS OR DIRECT INVESTMENTS IN ADDITIONAL PRIVATE EQUITIES. BARDA APPROVED ADDITIONAL FUNDING TO THE CORPORATION OF APPROXIMATELY $43,000,000. IN ADDITION, THE CORPORATION ENTERED INTO A SIMILAR STRATEGIC FUNDING AND COLLABORATION ARRANGEMENT WITH THE MITRE CORPORATION OF WHICH THE CORPORATION IS TO RECEIVE $10,000,000 FOR VENTURE INVESTMENTS MADE BY THE CORPORATION PURSUANT TO THE AGREEMENT. THE CORPORATION MADE $10,000,000 OF DIRECT FUNDING IN PRIVATE EQUITY SECURITIES.